Related Experiment Videos
Treatment of acute profound heart failure by ventricular assist device
H Takano1, T Nakatani, Y Taenaka
1National Cardiovascular Center, Department of Artificial Organs, Osaka, Japan.
Insights
Left ventricular assist device (LVAD) therapy aids recovery in profound heart failure (HF). Early LVAD application is crucial to prevent irreversible organ damage and improve long-term survival, even after heart recovery.
Area of Science:
- Cardiovascular Medicine
- Mechanical Circulatory Support
- Heart Failure Treatment
Background:
- Acute profound heart failure (HF) presents significant therapeutic challenges.
- Conventional treatments like intra-aortic balloon pumping (IABP) may be insufficient for severe cases.
- Left ventricular assist devices (LVADs) offer advanced mechanical circulatory support.
Purpose of the Study:
- To evaluate the efficacy of LVAD in treating patients with acute profound heart failure.
- To explore the potential for myocardial recovery and long-term survival with LVAD support.
- To establish a therapeutic concept for acute HF management using assisted circulation.
Main Methods:
- Treatment of sixteen patients with acute profound HF using LVAD.
- Monitoring of LV decompression, myocardial recovery, and overall patient survival.
- Comparison of LVAD effectiveness against IABP limitations.
Main Results:
- Nine out of sixteen patients were successfully weaned from LVAD support.
- Three patients were discharged and achieved longer-term survival.
- LVAD provided effective circulatory support, allowing time for myocardial recovery.
Conclusions:
- Continuous LVAD assistance facilitates recovery in profound heart failure.
- Timely LVAD intervention, before irreversible organ damage, is critical for successful outcomes.
- LVAD represents a powerful therapeutic option for acute HF beyond IABP capabilities.
Abstract:
Sixteen patients with acute profound heart failure (HF) have been treated with the left ventricular assist device (LVAD), nine of them were successfully weaned from LVAD, and three of them were discharged and survived longer. Decompression of the left ventricle (LV) at the beginning will prevent overextension of impaired myocardium and accelerate scar formation. Gradual increase of LV work will promote the compensation ability of the residual myocardium. We found that continuous LVAD assistance can give time for the impaired heart to recover while maintaining normal circulation. For patients with profound HF which is beyond the limit of intra-aortic balloon pumping's (IABP) capability, LVAD is a more powerful and effective means. Although the heart recovered, many patients later died of multiple organ failure (MOF) which was probably caused by prolonged ischemia before LVAD application. For completely successful recovery from profound HF, diagnosis and deciding to use LVAD should not be delayed. It should be applied before major organs including the heart itself suffer irreversible damage. We have established a systematic therapeutic concept of treating acute HF patients using assisted circulation including LVAD.